Robin Straathof

Robin Straathof

Auto-generated profile, based on publicly available information

Robin Straathof

Delft University of Technology, Department of Biomechanical Engineering, Delft, The Netherlands

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2024 in Brachytherapy
Verified
Journal Article
Open access
SVSharline M. van Vliet–Pérez
Sharline M. van Vliet–Pérez
RPRosemarijn van Paassen
Rosemarijn van Paassen
LWLinda S.G.L. Wauben
Linda S.G.L. Wauben
RSRobin Straathof
Robin Straathof
NBNick J. van de Berg
Nick J. van de Berg
RNRemi A. Nout
Remi A. Nout
Although MRI-based image guided adaptive brachytherapy (IGABT) for locally advanced cervical cancer (LACC) has resulted in favorable outcomes, it can be logistically complex and time consuming compared to 2D image-based brachytherapy, and both physically and emotionally intensive for patients. This prospective study aims to perform time-action and patient experience analyses during IGABT to guide further improvements. LACC patients treated with IGABT were included for the time-action (56 patients) and patient experience (29 patients) analyses. Times per treatment step were reported on a standardized form. For the patient experience analysis, a baseline health status was established with the EQ-5D-5L questionnaire and the perceived pain, anxiety and duration for each treatment step were assessed with the NRS-11. The median total procedure time from arrival until discharge was 530 (IQR: 480-565) minutes. Treatment planning (delineation, reconstruction, optimization) required the most time and took 175 (IQR: 145-195) minutes. Highest perceived pain was reported during applicator removal and treatment planning, anxiety during applicator removal, and duration during image acquisition and treatment planning. Perceived pain, anxiety and duration were correlated. Higher pre-treatment pain and anxiety scores were associated with higher perceived pain, anxiety and duration. This study highlights the complexity, duration and impact on patient experience of the current IGABT workflow. Patient reported pre-treatment pain and anxiety can help identify patients that may benefit from additional support. Research and implementation of measures aiming at shortening the overall procedure duration, which may include logistical, staffing and technological aspects, should be prioritized.

25 November 2024 in Physics in Medicine & Biology
Verified
Journal Article
Open access
RSRobin Straathof
Robin Straathof
SVSharline M van Vliet-Pérez
Sharline M van Vliet-Pérez
IKInger-Karine K Kolkman-Deurloo
Inger-Karine K Kolkman-Deurloo
LWLinda S G L Wauben
Linda S G L Wauben
RNRemi A Nout
Remi A Nout
NBNick J. van de Berg
Nick J. van de Berg
Purpose. Patient-tailored intracavitary/interstitial (IC/IS) brachytherapy (BT) applicators may increase dose conformity in cervical cancer patients. Current configuration planning methods in these custom applicators rely on manual specification or a small set of (straight) needles. This work introduces and validates a two-stage approach for establishing channel configurations in the 3D printed patient-tailored ARCHITECT applicator. Methods. For each patient, the patient-tailored applicator shape was based on the first BT application with a commercial applicator and integrated connectors to a commercial (Geneva) intrauterine tube and two lunar ring channels. First, a large candidate set was generated of channels that steer the needle to desired poses in the target region and are contained in the applicator. The channels’ centrelines were represented by Bézier curves. Channels running between straight target segments and entry points were optimised and refined to ensure (dynamic) feasibility. Second, channel configurations were selected using geometric coverage optimisation. This workflow was applied to establish patient-tailored geometries for twenty-two patients previously treated using the Venezia applicator. Treatment plans were automatically generated using the in-house developed algorithm BiCycle. Plans for the clinically used configuration, T P clin , and patient-tailored configuration, T P arch , were compared. Results. Channel configurations could be generated in clinically feasible time (median: 2651 s, range 1826–3812 s). All T P arch and T P clin plans were acceptable, but planning aims were more frequently attained with patient-tailored configurations (115/132 versus 100/132 instances). Median CTVIR D 98 and bladder D 2 c m 3 doses significantly improved ( p < 0.001 and p < 0.01 respectively) in T P arch plans in comparison with T P clin plans, and in approximately half of the patients dosimetric indices improved. Conclusion. Automated patient-tailored BT channel configuration planning for 3D printed applicators is clinically feasible. A treatment planning study showed that all plans met planning limits for the patient-tailored configurations, and in selected cases improved the plan quality in comparison with commercial applicator configurations.

10 June 2025 in Physics in Medicine & Biology
Verified
Journal Article
Open access
PDF file
IAIoannis Androulakis
Ioannis Androulakis
MLMyra van Laar
Myra van Laar
JGJeremy Godart
Jeremy Godart
RSRobin Straathof
Robin Straathof
HWHenrike Westerveld
Henrike Westerveld
IKInger-Karine K Kolkman-Deurloo
Inger-Karine K Kolkman-Deurloo
Objective. In brachytherapy for gynecological cancers using intracavitary applicators, implant reconstruction is commonly performed using applicator libraries. These libraries contain applicator geometry models as well as dwell position (DP) models defined in respect to the applicator geometry. In this study, we investigate whether an afterloader integrated electromagnetic tracking (EMT) system can be utilized for DP model definition and quality assurance in such applicators. Approach. DPs in four sets of two configurations of the Elekta Venezia Advanced Gynaecological Applicator (22 mm ovoids/40 mm intrauterine (IU) and 26 mm ovoids/70 mm IU) were measured using an afterloader integrated EMT system. Measurements were evaluated for reproducibility and compared against manufacturer-specified (MS) DPs and a computed tomography (CT)-corrected DP model. Main Results. Excellent EMT measurement reproducibility was observed, with values of ⩽0.2 mm for both configurations. The overall reproducibility, including applicator geometry reproducibility, was ⩽0.4 mm for both configurations. Significant discrepancies from the manufacturer’s DP model were observed, with a mean ± sd deviation of 1.13 ± 0.66 mm (22/40) and 1.37 ± 0.63 (26/70), particularly in the IU channel, where MS DPs were not experimentally defined. Discrepancies were reduced to 0.89 ± 0.41 mm (22/40) and 0.81 ± 0.33 mm (26/70) when the CT-corrected DP model was used as baseline, highlighting the need for experimentally defined DP models. The overall uncertainty of single measurements was below the clinically acceptable 2 mm limit. Significance. This study confirms that afterloader integrated EMT can accurately reconstruct source paths in gynecological brachytherapy applicators and supports its incorporation into clinical workflows for improved quality assurance and treatment precision. The importance of EMT for quality assurance was highlighted by measured deviations from manufacturer’s DP model in a clinical relevant part of the IU channel.

24 December 2025 in Brachytherapy
Verified
Journal Article
Open access
RSRobin Straathof
Robin Straathof
LPLotte I. Pool
Lotte I. Pool
SVSharline M. van Vliet-Pérez
Sharline M. van Vliet-Pérez
IKInger-Karine K. Kolkman-Deurloo
Inger-Karine K. Kolkman-Deurloo
BHBen J.M. Heijmen
Ben J.M. Heijmen
NBNick J. van de Berg
Nick J. van de Berg
Although dose planning aims in cervical cancer brachytherapy are well-defined, variability in clinical practices makes it difficult to draw generalizable conclusions on achievable dosimetry. This review and meta-regression aim to assess clinical practices in terms of their therapeutic dose window, that is, the balance between target and organs-at-risk (OAR) doses. A search of the literature was performed in Scopus, PubMed, and Web of Science databases. Peer-reviewed articles were included that described planning constraints and reported high-risk clinical target volume (CTVHR) D90% and OAR [Formula: see text] for intracavitary (IC) tandem and ring (T&R) / tandem and ovoid (T&O) / mold (M) applicators, possibly supplemented with interstitial (IS) needles (+N). To determine factors associated with target volume coverage (D90%) and OAR sparing ( [Formula: see text] ), multivariate meta-regressions were performed. Out of 1590 articles, 34 met the full inclusion criteria. In most studies, the CTVHRD90% aimed at ≥84-86 Gy EQD2α/β = 10Gy, and constraints for the OARs were 80-90 Gy, 65-75 Gy and 70-75 Gy EQD2α/β = 3Gy for the bladder, rectum and sigmoid [Formula: see text] , respectively. Studies using IC/IS applicators were associated with a ∼4 Gy increase in CTVHRD90% compared to IC only, with no effect on OAR dose. T&R studies achieved improvements of 3.2 Gy and 2.8-3.4 Gy at typical planning aims in comparison with T&O applicators in target and OAR doses. In 100% (15/15) of patient groups treated with T&R + N both CTVHR and OAR objectives were met for the population average. For T&R, T&O, and T&O + N groups, this was the case in 89% (8/9), 43% (6/14), and 50% (4/8), respectively. Studies using interstitial needles with T&R applicators in MR-guided brachytherapy for cervical cancer seem to be associated with a favorable therapeutic target dose/OAR sparing ratio.

12 April 2026 in Physica Medica
Verified
Journal Article
Open access
RSRobin Straathof
Robin Straathof
SVSharline M. van Vliet-Pérez
Sharline M. van Vliet-Pérez
LWLinda S.G.L. Wauben
Linda S.G.L. Wauben
BHBen J.M. Heijmen
Ben J.M. Heijmen
HWHenrike Westerveld
Henrike Westerveld
NBNick J. van de Berg
Nick J. van de Berg
Clinical introduction of in-house developed medical devices in Europe requires conformity to the Medical Device Regulation (MDR) 2017/745 Article 5(5). Published experience on regulatory aspects of these devices is limited. This work describes our in-house development and verifications of the 3D printed patient-tailored ARCHITECT brachytherapy applicator and accompanying software, prepared to support clinical investigation and in-house use. Article 5(5) mandates an 'appropriate' quality management system (QMS) and exempts in-house medical devices from all MDR requirements except general safety and performance requirements (GSPRs). An institutional QMS was available, comprising documented procedures and fill-in templates for all project phases to compile technical documentation. In the first phase, the QMS requires a market analysis to justify the in-house exemption. In the design phase a prototype is developed, to be iteratively improved during manufacturing and verification phases, based on risk evaluations, verification tests, and processing constraints. Documentation is lastly compiled to support clinical investigations and routine use of the device. After confirming that no suitable marketed device was available, risk-based design and manufacturing approaches were used to safeguard in-house development. Verifications of material, manufacturing, mechanical safety, cleaning and sterilisation, use and workflow, and compatibility with procedures showed compliance with GSPRs. Simulated dosimetric benefits were observed compared to marketed devices. The ARCHITECT applicator was developed in a systematic process, resulting in documented workflows and verification steps. Our approach provides a practical framework for MDR-compliant introduction of in-house equipment and can inform future best practice guidelines.